Yingxue Fu

The paper develops a multi-omics cohort of prefrontal cortex data from cognitively normal older adults to identify molecular signatures of cognitive resilience to Alzheimer's disease.

This study evaluates false discovery rate and statistical power in DIA proteomics using technical replicates and spike-in experiments, revealing discrepancies between nominal and true FDR and showing power dependence on fold change and abundance.

JUMPlion improves DIA proteomics by recovering missing ion-level values, enhancing protein quantification accuracy in low-input and single-cell analyses.

The paper quantifies the proteomic composition of amyloid plaques in AD models and human brains, revealing stage-dependent remodeling and conserved proteins across species.

Alzheimer's mouse model proteomes capture 30% (amyloid-only models) to 42% (adding tau and splicing models) of consensus human AD protein changes; in 5xFAD, plaques slow degradation of plaque-associated proteins.

The paper identifies an AD-like subtype in brain aging across multiple regions, showing overlap with AD gene signatures and regional differences in gene expression.

The paper uses integrated proteomics to identify autophagy targets and receptors in human neurons, revealing their role in degradation and neuronal activity regulation.

NOGEA identifies master genes driving disease initiation and comorbidity, predicts drug-disease associations, and validates new drug candidates for pancreatic cancer.

This study identifies key regulators of epileptogenesis in temporal lobe epilepsy using systems-level analysis of transcriptomic data from rodent models and human patients.

This study shows that methylglyoxal (MGO) enhances resilience to chronic stress and alleviates depression-like symptoms by promoting synaptic plasticity through TrkB activation and BDNF expression.